Healios K.K. (TSE: 4593)
Health Care · Biotechnology · JP
¥302.00
+5.23% today · -35.5% 1Y
Healios K.K. (TSE: 4593) operates in the Biotechnology industry within the Health Care sector. The company is valued at $258.52M and employs 75 people.
Over the last twelve months the share price has lost 35.5%, trading between 208.00 and 514.00.
Tweenvest scores Healios K.K. across four factors: quality 38/100, value 30/100, growth 100/100. Its strongest factor is growth.
4593 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $258.52M
- Revenue (TTM)
- $362.98K
- P/E
- —
- EPS
- -7.51
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- ¥514.00
- 52-week low
- ¥208.00
- Avg volume (3M)
- —
- Shares outstanding
- 135.55M
- Employees
- 75
- Next earnings
- —
About Healios K.K.
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
- ISIN
- JP3835100003
- Founded
- 2011
- Listed since
- Jun 16, 2015
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Obigen Pharma Inc.TPEX: 7876 | $262.25M | NT$78.20 | +21.81% |
| Anika Therapeutics, Inc.NasdaqGS: ANIK | $262.04M | $19.58 | +1.82% |
| Fate Therapeutics, Inc.NasdaqGM: FATE | $261.21M | $2.11 | -3.21% |
| VISEN PharmaceuticalsSEHK: 2561 | $259.19M | HK$18.61 | +0.59% |
| Upstream Bio, Inc.NasdaqGS: UPB | $257.42M | $4.70 | -6.75% |
| PharmaEngine, Inc.TPEX: 4162 | $257.02M | NT$57.20 | +3.25% |
| Immuneering CorporationNasdaqGM: IMRX | $254.91M | $3.94 | -3.19% |
| Amarin Corporation plcNasdaqCM: AMRN | $254.11M | $12.03 | -2.59% |
Figures last refreshed Oct 11, 2026.